GO
Loading...

GlaxoSmithKline PLC

More

  • Merck And Schering Plough: "Enhancing" A Franchise? Monday, 14 Jan 2008 | 2:13 PM ET

    The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)

  • The 'Supply Chain': Stocks That Beat the S&P Thursday, 10 Jan 2008 | 4:42 PM ET

    Kevin O'Marah, chief strategist at AMR Research, has developed a unique "supply-chain strategy" -- and uses it to compile a Top 25 stocks list that beat the 2007 market hands-down.

  • FDA Approves Daily Cialis Doses Tuesday, 8 Jan 2008 | 10:34 AM ET

    Eli Lilly Tuesday said U.S. regulators approved once-daily use of two low-dose forms of its Cialis anti-impotence drug, offering greater convenience for men expecting frequent sexual activity.

  • My 7 For '07: The Pharma Year in Review Friday, 28 Dec 2007 | 1:57 PM ET

    The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.

  • Glaxo's Avandia Scare: Market Feels Effects Thursday, 27 Dec 2007 | 10:46 AM ET

    A Merrill Lynch research note to clients titled, "Diabetics scared off therapy," contains some interesting observations about what's happened to the oral diabetes drug market in the wake of the Avandia safety scare earlier this year.

  • Eli Lilly

    Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.

  • Amgen: Is It Down To "The Bone" For Investors? Monday, 17 Dec 2007 | 12:32 PM ET

    Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.

  • Glaxo Cervical Cancer Vaccine Hit by Delay in FDA OK Monday, 17 Dec 2007 | 8:13 AM ET

    GlaxoSmithKline's cervical cancer vaccine Cervarix faces a delay in winning approval in the United States, putting it further behind Merck's rival product Gardasil.

  • Glaxo Drug May Help Shrink Metastatic Brain Tumors Sunday, 16 Dec 2007 | 11:46 AM ET

    Study results show the new oral drug Tykerb from GlaxoSmithKline, combined with chemotherapy, may shrink metastatic brain tumors.

  • Novartis Cuts, While Biogen Idec Cuts And Runs Thursday, 13 Dec 2007 | 4:06 PM ET
    Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Glaxo says Viehbacher Joins Board, Stout to Leave Friday, 7 Dec 2007 | 10:36 AM ET

    One of two top executives who lost out two months ago in the race to become chief executive of GlaxoSmithKline Plc is joining the board, while the other is to leave, Europe's biggest drugmaker said on Friday.

  • The popular diabetes drug marketed as Avandia may increase bone thinning, a discovery that could help explain why diabetics can have an increased risk of fractures.

  • Late yesterday, a bullet crossed the Dow Jones newswire saying, "FDA Warns GlaxoSmithKline on Breast-Cancer Drug Promotion." Almost immediately, my producer and I got a call from the CNBC staffer who was manning what we call our "Alerts Desk" asking us if we'd seen the news and if we could provide any context.

  • Glaxo to Buy Heart Drug Firm Reliant for $1.65 Billion Wednesday, 21 Nov 2007 | 10:01 AM ET

    GlaxoSmithKline has agreed to buy privately held heart drug specialist Reliant Pharmaceuticals for $1.65 billion in cash, Europe's biggest pharmaceuticals group said on Wednesday.

  • It didn't take long for Japan's Takeda Pharmaceuticals, which trades on the Tokyo exchange, to try to capitalize on the new safety warning for GlaxoSmithKline's diabetes drug Avandia. Last week the FDA slapped a so-called "Black Box"--the agency's most severe warning--on the Avandia label advising patients and doctors about the potential heart attack and stroke risk that's been the subject of so much controversy over the past several months.

  • Eli Lilly: Will They Get Lucky With 'One A Day' Cialis? Wednesday, 31 Oct 2007 | 3:36 PM ET
    Eli Lilly

    Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa

  • Market Insider/Wednesday Look Ahead Wednesday, 31 Oct 2007 | 11:23 AM ET

    Buying in tech stocks could lift the market again Wednesday, but Merrill Lynch earnings hang in front of the opening bell like a dark cloud. Or should we say Merrill's report of losses. The firm is scheduled to report third quarter numbers between 7:30 and 8 a.m., and analysts are forecasting a loss of $0.45 per share.

  • Merck, Sanofi, Glaxo Get "Shot In The Arm" From U.K. Friday, 26 Oct 2007 | 12:52 PM ET

    British health authorities today announced that starting next fall, all 12- and 13-year-old girls will have to get the controversial shots to prevent the sexually transmitted virus that can lead to cervical cancer. Merck and Sanofi-Aventis are partners on the vaccine Gardasil and the UK-based GlaxoSmithKline makes a similar one Cervarix.

  • Stocks Reverse Most Losses on Rate-Cut Rumors Wednesday, 24 Oct 2007 | 6:09 PM ET

    Stocks closed mixed after reversing an earlier selloff, helped by rumors circulated that the Federal Reserve would soon cut the discount rate.

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.